TSTickerStarGet alerts
Company alerts/GCTK
GCTK company alerts

GCTK updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for GCTK. Subscribe to GCTK alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for GCTK alertsView companies
Official-source feed

Recent GCTK alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company updateOfficial company source

Glucotrack Receives Nasdaq Delisting Notice; Trading to Suspend October 30

Glucotrack, Inc. received written notice from the Nasdaq Hearings Panel that its securities will be delisted because the company's closing bid price was $0.87 on October 14, 2026, failing to satisfy the terms of a compliance exception that required maintaining a closing bid price of at least $1.00 for each trading day through November 9, 2026. Trading in the company's common stock on Nasdaq will be suspended at the open of trading on October 30, 2026. The company expects its shares to be quoted by OTC Markets Gr...

Read source-backed brief
Company updateOfficial company source

Lokahi merger pro forma financials and 1-for-2 reverse stock split

Glucotrack's unaudited pro forma financial information gives effect to its July 14, 2026 merger with Lokahi Therapeutics, with $34,290,345 of consideration transferred; an EV/sales multiple is not calculable because Lokahi reported no revenue for FY2025 or the six months ended June 30, 2026. Pro forma combined revenue was $0 and net loss was $(19,699,822) for the six months ended June 30, 2026, versus a pro forma combined net loss of $(28,135,308) for FY2025. The filing also reports a 1-for-2 reverse stock split...

Read source-backed brief
Debt offeringSEC filing

Glucotrack Raises $2M via Private Placement of Convertible Notes and Announces 1-for-2 Reverse Stock Split

Glucotrack, Inc. entered into a securities purchase agreement on October 22, 2026, issuing senior secured convertible promissory notes in aggregate principal amount of $2,564,102.65 for cash proceeds of $2,000,000, reflecting a 22% original issue discount. The notes bear interest at 8% per annum, mature in nine months, and are convertible at the lower of $0.6390 (Nasdaq Minimum Price) or 80% of the lowest VWAP during the 15 trading days preceding conversion, subject to a floor price equal to 20% of the Nasdaq Mi...

Read source-backed brief
Debt offeringSEC filing

Glucotrack enters Waiver Agreement and issues New Warrants for 406,198 shares at $7.50 exercise price

On October 13, 2026, Glucotrack, Inc. entered into a Waiver Agreement with holders of warrants originally issued under the July 14, 2026 Securities Purchase Agreement, terminating the Equity Issuance Restriction Right under Section 5.10(a) of the Purchase Agreement (effective as to all Holders) and waiving the VRT Adjustment Right under Section 3(e) of the Existing Warrants (effective only as to executing Holders). In consideration, the Company agreed to issue New Warrants to purchase an aggregate of 406,198 sha...

Read source-backed brief
Debt offeringSEC filing

Glucotrack files preliminary proxy for special meeting covering September Financing share issuance, PIPE Warrant issuance, and reverse stock split

Glucotrack, Inc. filed a preliminary proxy statement (Schedule 14A) for a special meeting of stockholders to vote on four proposals: (1) Nasdaq Listing Rule 5635(d) approval for the full issuance of shares issuable upon conversion of senior secured convertible notes (the September Notes) and exercise of common stock purchase warrants issued on September 10, 2026, (2) Nasdaq Listing Rule 5635(d) approval for the full issuance of shares issuable upon exercise of the PIPE Warrant from the August 4, 2026 Interim PIP...

Read source-backed brief